Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2025-07-11 Share Issue/Capital Cha…
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Xbrane publishes disclosure document regarding admission to trading of the newly issued shares in Xbrane
Share Issue/Capital Change Classification · 95% confidence The document is a press release titled "Xbrane publishes disclosure document regarding admission to trading of the newly issued shares in Xbrane." It details a recent 'Directed Share Issue' resolved by the board and approved by an extraordinary general meeting. Crucially, it states that a 'disclosure document in accordance with Article 1.5... of Regulation (EU) 2017/1129 regarding the admission to trading of the newly issued shares... has been registered with the Swedish Financial Supervisory Authority' and is available on the website. The content focuses on the mechanics of a capital raise (share issue) and the subsequent regulatory filing/disclosure document related to that capital change, rather than being the full financial report (10-K or IR) or the formal notice of the meeting (DEF 14A/PSI). Since the core action is announcing the completion/registration of documentation related to a share issue, it strongly aligns with Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS). Given the explicit mention of the share issue, the 'CAP' code is the most specific fit for the underlying corporate action being announced. The document itself is an announcement, not the full disclosure document.
2025-07-11 English
Xbrane offentliggör undantagsdokument avseende upptagande till handel av de nyemitterade aktierna i Xbrane
Share Issue/Capital Change Classification · 95% confidence The document is a press release from Xbrane Biopharma AB announcing the registration of an 'undantagsdokument' (exemption prospectus/document) with the Swedish Financial Supervisory Authority (Finansinspektionen) concerning the admission to trading of newly issued shares following a directed share issue. The text explicitly states that this document is NOT a prospectus under the Prospectus Regulation (EU) 2017/1129. Since the document is an announcement about the publication/registration of a regulatory document related to a capital action (share issue) and is structured as a press release detailing the event and its implications, it fits best as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP). Given the focus is on the regulatory filing process itself ('offentliggör undantagsdokument avseende upptagande till handel'), and it is not the full financial report (10-K, IR) or a specific capital change announcement (SHA), RNS serves as the most appropriate general regulatory announcement category, although CAP is also relevant due to the underlying share issue. However, the core action described is the regulatory publication related to the listing, making RNS the strongest fit for this type of announcement, especially since it is not a standard 'Report Publication Announcement' (RPA) which usually announces the release of a standard report like an Annual Report or Interim Report. I will classify it as RNS as it is a general regulatory announcement regarding a specific corporate action filing.
2025-07-11 Swedish
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
AGM Information Classification · 98% confidence The document is titled "Kommuniké från extra bolagsstämma i Xbrane Biopharma AB" (Communiqué from the Extraordinary General Meeting in Xbrane Biopharma AB) and details decisions made by shareholders regarding a directed new share issue (nyemission). This content directly relates to shareholder meetings and the resulting corporate actions. Since the document explicitly reports the decisions made at a General Meeting, it aligns best with the 'AGM Information' category, even though it is an 'Extraordinary' meeting rather than the Annual General Meeting (AGM). The core function is reporting meeting outcomes. The presence of a link to a PDF attachment suggests it is the official release of the meeting results. Therefore, AGM-R is the most appropriate classification.
2025-07-03 Swedish
Announcement from extra general meeting in Xbrane Biopharma AB
AGM Information Classification · 95% confidence The document explicitly announces resolutions passed at an 'extra general meeting' (EGM). The primary resolution concerns a 'directed issue of shares' (a financing/capital activity) approved by the shareholders. While it details a capital change (SHA), the context is the formal outcome of a shareholder meeting, which often relates to AGM/EGM materials. However, the core content is the approval of a share issuance (CAP/SHA). Since the document is the official announcement of the results of a shareholder vote regarding a specific corporate action (share issuance), it is most closely related to the outcomes of a general meeting. Given the options, 'AGM-R' covers general meeting results, and 'CAP' covers the share issue itself. Since the document is the *announcement* of the resolutions passed at the meeting, and it details a significant capital raising activity, 'CAP' (Capital/Financing Update) is highly relevant, but 'AGM-R' (AGM Information) covers the meeting context. Since the text is the official record of resolutions passed at a general meeting, 'AGM-R' is the most appropriate classification for the meeting outcome announcement, even though the resolution itself is about capital. If the resolution was the primary focus without the meeting context, CAP would fit better. Given the header 'Announcement from extra general meeting' and the reporting of 'resolutions were passed', AGM-R is selected.
2025-07-03 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I XBRANE BIOPHARMA AB
AGM Information Classification · 98% confidence The document is titled 'KALLELSE TILL EXTRA BOLAGSSTÄMMA I XBRANE BIOPHARMA AB' (Notice of Extraordinary General Meeting in Xbrane Biopharma AB). It details the date, time, location, registration procedures, agenda, and proposed resolutions for an upcoming shareholder meeting. Specifically, it includes a proposal for a directed new share issue (Punkt 6). This content is characteristic of a formal notice calling shareholders to a meeting, which aligns with the purpose of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM) notice. Since the definition for AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)', and this is the formal notice/call for such a meeting, AGM-R is the most appropriate classification, even though it is an 'Extra' meeting, as there is no specific code for EGM notices, and AGM-R covers the general category of shareholder meeting materials/calls.
2025-06-10 Swedish
NOTICE OF EXTRA GENERAL MEETING IN XBRANE BIOPHARMA AB
AGM Information Classification · 99% confidence The document is explicitly titled "NOTICE OF EXTRA GENERAL MEETING IN XBRANE BIOPHARMA AB". It details the date, time, location, registration procedures, proposed agenda items (including a resolution on a directed share issue), and voting requirements for an upcoming shareholder meeting. This content directly corresponds to the purpose of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM) notice/materials. Since the definition for AGM-R covers presentations and materials shared during the AGM, and this is the formal notice convening such a meeting, AGM-R is the most appropriate classification. It is not a full Annual Report (10-K), an Earnings Release (ER), or a proxy statement (PSI), but rather the official call to the meeting.
2025-06-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.